Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Wells Syndrome (Eosinophilic Cellulitis) : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
References

Related Articles
Cellulitis

Churg-Strauss Syndrome (Allergic Granulomatosis)

Contact Dermatitis, Allergic

Drug Eruptions

Drug-Induced Bullous Disorders

Erysipelas

Granuloma Annulare

Hypereosinophilic Syndrome

Insect Bites

Lyme Disease

Urticaria, Chronic




Patient Education
Click here for patient education.



Author: Justin Brown, MD, Staff Physician, Department of Dermatology, UMDNJ-New Jersey Medical School

Justin Brown is a member of the following medical societies: Alpha Omega Alpha and Sigma Xi

Coauthor(s): Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School

Editors: Takeji Nishikawa, MD, Emeritus Professor, Department of Dermatology, Keio University School of Medicine; Director, Samoncho Dermatology Clinic; Managing Director, The Waksman Foundation of Japan Inc; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Rosalie Elenitsas, MD, Associate Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center

Author and Editor Disclosure

Synonyms and related keywords: recurrent granulomatous dermatitis with eosinophilia, Wells' syndrome, Well's syndrome

Background

In 1971, George Wells first described this syndrome as a recurrent granulomatous dermatitis with eosinophilia. Wells and Smith renamed it eosinophilic cellulitis in 1979.

Eosinophilic cellulitis (Wells syndrome) is an uncommon condition of unknown etiology. The presentation usually involves a mildly pruritic or tender cellulitislike eruption with typical histologic features characterized by edema, flame figures, and a marked infiltrate of eosinophils in the dermis. Papular and nodular eruptions at the clinical presentation have also been reported. The condition can recur and may be preceded by a pruritic papular eruption. Although Wells syndrome is usually sporadic, some familial cases have been reported.

One study showed the successive occurrence of vasculitis, Wells syndrome, and Sweet syndrome in a patient. This finding suggests that an overlap between these diseases exists (Consigny, 2001). Another report describes a dominant syndrome consisting of eosinophilic cellulitis, mental retardation, and abnormal body habitus in one family (Davis, 1998).

Pathophysiology

The etiology is unknown. At least some cases may represent hypersensitivity to an arthropod bite or sting. A dermal infiltrate of histiocytes, eosinophils, and eosinophilic granules occurs between collagen bundles, which forms the classic flame figures. The eosinophilic infiltrate is almost always restricted to the epidermis and the dermis, but it has also been found in the subcutaneous tissue and the underlying muscle. The location of the infiltrate is correlated with the different clinical features.

In one study, immunophenotyping of peripheral T cells revealed an increased proportion of CD3+ and CD4+T cells (Plotz, 2000). These lymphocytes spontaneously release significant amounts of interleukin 5 (IL-5); this finding suggests that activated T cells may be involved in the pathogenesis of blood and tissue eosinophilia. The eosinophils then degranulate in the dermis, causing edema and inflammation.

With immunofluorescent stains, eosinophil major basic protein is identified in the granules of the flame figures. On electron microscopy, the collagen fibers are intact; this finding suggests that an initial degeneration of collagen is not a factor in initiating the formation of flame figures.

Eosinophilic cellulitis may be due to drugs, various infections, and, possibly, nonhematological malignancies as trigger events (Hirsch, 2005). Wells syndrome has also been reported to occur in patients with hypereosinophilic syndrome and Churg-Strauss syndrome.

Frequency

United States

Wells syndrome is rare.

International

Only about 80 cases have been reported internationally, including domestically.

Mortality/Morbidity

Although long-term sequelae usually do not result, reticular pigmentation and scarring alopecia may occur.

Race

Wells syndrome can occur in persons of any race.

Sex

No sexual predilection is reported.

Age

Wells syndrome usually affects adults, but it has been known to occur in children. In one case series of 19 patients, the classic plaque-type presentation was the most common variant found in children, while the annular granuloma–like variant was the most common variant in adults (Caputo, 2006).



History

  • Usually, the patient complains of pruritus or a burning sensation, which is followed by erythema and edema.
  • The clinical presentation can vary widely and may include the following:
    • Annular plaques
    • Vesicles and bullae
    • Urticaria
    • Edema
    • Papules or nodules
  • Typically, a tender or mildly pruritic cellulitislike eruption occurs.
  • Occasionally, papular and nodular eruptions may be seen first.
  • Systemic symptoms, including asthma, arthralgia, and fever, may be evident, although they usually do not occur.

Physical

  • The lesions progress over a few days to become large, indurated plaques of edema and erythema, with violaceous edges and no calor.
  • The lesions may last for several weeks, but they gradually darken from bright red to slate blue.
  • Complete resolution with no scarring is typical, although scarring alopecia may occur.
  • The plaques can occur anywhere on the skin, and they may be solitary or multiple.
  • Plaques on the affected areas are known to recur, and vesiculobullae may develop over the surface.
  • The clinical features seem to depend on the location of the infiltrates in the dermis. This observation suggests that a spectrum of eosinophilic dermatoses occurs in Wells syndrome.

Causes

  • The etiology is unknown.
  • Wells syndrome is usually sporadic, but some familial cases have been described.
  • Suggested precipitating factors include the following:
    • Arthropod bites
    • Cutaneous viral infections
    • Cutaneous parasitic infestations, including toxocariasis, ascariasis, and onchocerciasis
    • Leukemia
    • Myeloproliferative disorders
    • Atopic dermatitis
    • Fungal infections
    • Hypersensitivity reactions to medications



Cellulitis
Churg-Strauss Syndrome (Allergic Granulomatosis)
Contact Dermatitis, Allergic
Drug Eruptions
Drug-Induced Bullous Disorders
Erysipelas
Granuloma Annulare
Hypereosinophilic Syndrome
Insect Bites
Lyme Disease
Urticaria, Chronic

Other Problems to be Considered

Toxocariasis



Lab Studies

  • Peripheral blood and bone marrow eosinophilia are usually present.
  • In peripheral blood, an increase in eosinophil cation protein (ECP) and IL-5 levels can be detected. Of note, the levels of ECP and IL-5 seem to be correlated with the severity of the disease.

Procedures

  • Eosinophilic cellulitis is usually diagnosed on the basis of the characteristic histopathologic findings in a skin biopsy specimen.

Histologic Findings

Skin biopsy specimens show a dermal infiltrate of eosinophils, histiocytes, and eosinophil debris between collagen bundles that forms flame figures. During the acute early phase, the dense infiltrate of degranulating eosinophils is usually located in the epidermis and the dermis, although it occasionally extends into the subcutaneous tissue and the underlying muscle.

Vesiculation can occur. The blisters contain eosinophils and are predominately subepidermal and, occasionally, multiloculated and spongiotic. The location of the infiltrate is correlated with the different clinical features.

After weeks, the flame figures are seen, along with a palisade of histiocytes and giant cells around some collagen fibers. With immunofluorescent stains, eosinophil major basic protein is identified in the granules of the flame figures. On electron microscopy, the collagen fibers are intact; this finding suggests that an initial degeneration of collagen is not a factor in initiating the formation of flame figures.

Although the histopathologic findings of eosinophilia, histiocytes, and flame figures are characteristic of Wells syndrome, they are also found in other conditions, including bullous pemphigoid, eczema, tinea infection, and insect bites.



Medical Care

  • Numerous treatment options include the use of topical corticosteroids, griseofulvin, H1 antihistamines, cyclosporine, dapsone, and systemic corticosteroids.
  • Systemic corticosteroids are the most effective treatment, but they may lead to corticosteroid dependence.



The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Drug Category: Antifungal

Mechanism of action usually involves inhibiting pathways (enzymes, substrates, transport) necessary for sterol/cell membrane synthesis or altering the permeability of the cell membrane (polyenes) of the fungal cell.

Drug NameGriseofulvin (Fulvicin P/G, Grifulvin V)
DescriptionFungistatic activity. Fungal cell division is impaired by interfering with microtubules. Binds to keratin precursor cells. Keratin is gradually replaced by noninfected tissue, which is highly resistant to fungal invasions.
Adult Dose500 mg microsize (330-375 mg ultramicrosize) PO qd or bid, continue for 2 wk after clinical lesions resolve
Pediatric DoseSuggested dose: 20 mg microsize/kg/d (5 mg/lb/d) PO or 7.3 mg ultramicrosize/kg/d (3.3 mg/lb/d) PO
ContraindicationsDocumented hypersensitivity; hepatic injury
InteractionsReduced effects of cyclosporine, salicylates, and warfarin (decreased hypoprothrombinemic activity); avoid alcohol use because disulfiramlike reaction may occur; intense UV light exposure may result in phototoxic reaction; contraceptives may lose their effectiveness
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsBetter absorption when taken with fatty food; adverse effects may include abdominal pain, nausea, diarrhea, headache and, rarely, Stevens-Johnson syndrome and photodermatitis; 20% of patients experience adverse effects; in prolonged therapy, observe patients closely; monitor renal, hepatic, and hematopoietic function regularly

Drug Category: Antibiotics

Therapy must cover all likely pathogens in the context of this clinical setting.

Drug NameDapsone (Avlosulfon)
DescriptionBactericidal and bacteriostatic against mycobacteria; mechanism of action is similar to that of sulfonamides where competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth.
Adult Dose50-300 mg PO qd
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; known G-6-PD deficiency
InteractionsMay inhibit anti-inflammatory effects of clofazimine; hematologic reactions may increase with folic acid antagonists, eg, pyrimethamine (monitor for agranulocytosis during second and third months of therapy); probenecid increases toxicity; trimethoprim with dapsone may increase toxicity of both drugs; because of increased renal clearance, levels may significantly decrease when administered concurrently with rifampin
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsPerform weekly blood counts (first mo), then monthly WBC counts (6 mo), then semiannually thereafter; discontinue if significant reduction in platelets, leukocytes, or hematopoiesis; caution in methemoglobin reductase deficiency, G-6-PD deficiency (patients receiving >200 mg/d), or hemoglobin M because of high risk for hemolysis and Heinz body formation; caution in patients exposed to other agents or conditions (eg, infection, diabetic ketosis) capable of producing hemolysis; peripheral neuropathy can occur (rare); phototoxicity may occur when exposed to UV light

Drug Category: Immunosuppressants

These agents inhibit key factors in the immune system responsible for immune reactions.

Drug NameCyclosporine (Sandimmune, Neoral)
DescriptionDemonstrated to be helpful in a variety of skin disorders.
Adult Dose2.5-5 mg/kg/d PO in divided doses
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; uncontrolled hypertension or malignancies; do not administer concomitantly with PUVA or UV-B radiation in psoriasis because it may increase risk of cancer
InteractionsCarbamazepine, phenytoin, isoniazid, rifampin, and phenobarbital may decrease concentrations; azithromycin, itraconazole, nicardipine, ketoconazole, fluconazole, erythromycin, verapamil, grapefruit juice, diltiazem, aminoglycosides, acyclovir, amphotericin B, and clarithromycin may increase toxicity; acute renal failure, rhabdomyolysis, myositis, and myalgias increase when taken concurrently with lovastatin; methylprednisolone and cyclosporine mutually inhibit one another, resulting in increased plasma levels of each drug
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsEvaluate renal and liver functions often by measuring BUN, serum creatinine, serum bilirubin, and liver enzyme levels; may increase risk of infection and lymphoma; reserve IV use only for those who cannot take PO

Drug NameCortisone (Cortone)
DescriptionDecreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Adult Dose25-300 mg/d PO/IM divided q12-24h
Pediatric Dose0.5-0.75 mg/kg/d PO/IM or 20-25 mg/m2/d divided q8h
Alternative IM administration: 0.25-0.35 mg/kg/d IM qd or 12.5 mg/m2/d
ContraindicationsDocumented hypersensitivity; viral, fungal, or tubercular skin lesions
InteractionsEstrogen coadministration may increase corticosteroid levels; may increase digitalis toxicity secondary to hypokalemia
PregnancyD - Unsafe in pregnancy
PrecautionsCaution in patients with hyperthyroidism, cirrhosis, nonspecific ulcerative colitis, osteoporosis, peptic ulcer, diabetes, and myasthenia gravis

Drug NamePrednisone (Orasone, Meticorten, Sterapred, Deltasone)
DescriptionMay decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
Adult Dose5-60 mg/d PO qd or divided bid/qid; taper over 2 wk as symptoms resolve
Pediatric Dose4-5 mg/m2/d PO; alternatively, 0.05-2 mg/kg PO divided bid/qid; taper over 2 wk as symptoms resolve
ContraindicationsDocumented hypersensitivity; viral, fungal, tubercular skin, or connective tissue infections; peptic ulcer disease; hepatic dysfunction; GI bleeding or ulceration
InteractionsCoadministration with estrogens may decrease clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAbrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use

Drug NameHydrocortisone (LactiCare-HC, Cortaid, Dermacort, Westcort, CortaGel)
DescriptionAn adrenocorticosteroid derivative suitable for application to skin or external mucous membranes. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.
Adult DoseApply sparingly to affected areas bid/qid
Pediatric DoseApply as in adults
ContraindicationsDocumented hypersensitivity; viral, fungal, and bacterial skin infections
InteractionsNone reported
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsProlonged use, applying over large surface areas, applying potent steroids, and use of occlusive dressings may increase systemic absorption of corticosteroids and may cause Cushing syndrome, reversible HPA-axis suppression, hyperglycemia, and glycosuria

Drug NameDexamethasone (Alba-Dex, Dexone, Baldex, AK-Dex, Decadron)
DescriptionFor various allergic and inflammatory diseases. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reducing capillary permeability.
Adult Dose0.75-9 mg/d IV/IM in divided doses q6-12h
Pediatric Dose0.08-0.3 mg/kg/d IV/IM or 2.5-10 mg/m2/d IV/IM divided q6-12h
ContraindicationsDocumented hypersensitivity; active bacterial or fungal infection
InteractionsEffects decrease with coadministration of barbiturates, phenytoin, and rifampin; decreases effect of salicylates and vaccines used for immunization
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsIncreases risk of multiple complications, including severe infections; monitor adrenal insufficiency when tapering; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications of glucocorticoid use

Drug NameBetamethasone (Topical) (Diprolene, Maxivate, Alphatrex)
DescriptionFor inflammatory dermatoses responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. Affects production of lymphokines and has inhibitory effect on Langerhans cells.
Adult DoseApply thin film bid/qid until response
Pediatric DoseApply as in adults with caution
ContraindicationsDocumented hypersensitivity; paronychia; cellulitis; impetigo; angular cheilitis; erythrasma; erysipelas; rosacea; perioral dermatitis; acne
InteractionsNone reported
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsDo not use in skin with decreased circulation; can cause atrophy of groin, face, and axillae; may cause striae distensae or rosacealike eruption; may increase skin fragility; rarely may suppress HPA axis; if infection develops and is not responsive to antibiotic treatment, discontinue until infection is controlled; do not use monotherapy to treat widespread plaque psoriasis

Drug Category: H1 receptor antagonists

These agents act by competitive inhibition of histamine at the H1 receptor. This mediates the wheal and flare reactions, bronchial constriction, mucous secretion, smooth muscle contraction, edema, hypotension, CNS depression, and cardiac arrhythmias.

Drug NameCyproheptadine (Periactin)
DescriptionFor the symptomatic relief of allergic symptoms caused by histamine released in response to allergens and skin manifestations.
Adult Dose4-20 mg PO qd, not to exceed 0.5 mg/kg/d; initiate therapy with 4 mg tid; dose range is 12-16 mg/d and occasionally up to 32 mg/d
Pediatric DoseCalculate total daily dose as 0.25 mg/kg (0.11 mg/lb) or 8 mg/m2
2-6 years: 2 mg PO bid/tid; not to exceed 12 mg/d
7-14 years: 4 mg PO bid/tid; not to exceed 16 mg/d
>14 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; narrow-angle glaucoma; stenosing peptic ulcer; symptomatic prostatic hypertrophy; bladder neck obstruction; pyloroduodenal obstruction; lower respiratory tract symptoms
InteractionsPotentiates effects of CNS depressants; MAOIs may prolong and intensify anticholinergic and sedative effects of antihistamines
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in patients with a predisposition to urinary retention, history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, or hypertension; may thicken bronchial secretions caused by anticholinergic properties and may inhibit expectoration and sinus drainage

Drug NameDiphenhydramine (Benylin, Benadryl)
DescriptionFor symptomatic relief of symptoms caused by release of histamine in allergic reactions.
Adult Dose25-50 mg PO q6-8h prn; not to exceed 400 mg/d
10-50 mg IV/IM q6-8h prn; not to exceed 400 mg/d
Pediatric Dose12.5-25 mg PO tid/qid; not to exceed 300 mg/d
5 mg/kg/d IV/IM or 150 mg/m2/d IV/IM divided qid; not to exceed 300 mg/d
ContraindicationsDocumented hypersensitivity; MAOIs
InteractionsPotentiates effect of CNS depressants; because of alcohol content, do not give syrup form to patient taking medications that can cause disulfiramlike reactions
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsMay exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, or urinary tract obstruction; xerostomia may occur



Complications

  • Rarely, Wells syndrome is associated with systemic disease, even some life-threatening diseases, including leukemia and lymphoma. However, at this point, determining if these are coincidental findings or real associations is impossible.

Prognosis

  • The prognosis for patients with eosinophilic cellulitis is excellent.
  • Eosinophilic cellulitis tends to resolve in weeks or months, usually without scarring. It occasionally recurs, and in these recurrent cases, it can take years to ultimately resolve.



  • Aberer W, Konrad K, Wolff K. Wells'' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol. Jan 1988;18(1 Pt 1):105-14. [Medline].
  • Anderson CR, Jenkins D, Tron V, Prendiville JS. Wells'' syndrome in childhood: case report and review of the literature. J Am Acad Dermatol. Nov 1995;33(5 Pt 2):857-64. [Medline].
  • Brehmer-Andersson E, Kaaman T, Skog E, Frithz A. The histopathogenesis of the flame figure in Wells'' syndrome based on five cases. Acta Derm Venereol. 1986;66(3):213-9. [Medline].
  • Brown J, Schwartz RA. Wells' syndrome (eosinophilic cellulitis). Cesko-Slovenska Dermatol. 2002;77:261-263.
  • Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. Sep 2006;142(9):1157-61. [Medline].
  • Consigny S, Courville P, Young P, et al. [Histological and clinical forms of the eosinophilic cellulitis]. Ann Dermatol Venereol. Mar 2001;128(3 Pt 1):213-6. [Medline].
  • Davis MD, Brown AC, Blackston RD, et al. Familial eosinophilic cellulitis, dysmorphic habitus, and mental retardation. J Am Acad Dermatol. Jun 1998;38(6 Pt 1):919-28. [Medline].
  • Espana A, Sanz ML, Sola J, Gil P. Wells'' syndrome (eosinophilic cellulitis): correlation between clinical activity, eosinophil levels, eosinophil cation protein and interleukin- 5. Br J Dermatol. Jan 1999;140(1):127-30. [Medline].
  • Falagas ME, Vergidis PI. Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern Med. Jan 4 2005;142(1):47-55. [Medline].
  • Fisher GB, Greer KE, Cooper PH. Eosinophilic cellulitis (Wells'' syndrome). Int J Dermatol. Mar 1985;24(2):101-7. [Medline].
  • Ghislain PD, Van Eeckhout P. Eosinophilic cellulitis of papulonodular presentation (Wells' syndrome). J Eur Acad Dermatol Venereol. Mar 2005;19(2):226-7. [Medline].
  • Herr H, Koh JK. Eosinophilic cellulitis (Wells'' syndrome) successfully treated with low- dose cyclosporine. J Korean Med Sci. Oct 2001;16(5):664-8. [Medline].
  • Hirsch K, Ludwig RJ, Wolter M, et al. Eosinophilic cellulitis (Wells' syndrome) associated with colon carcinoma. J Dtsch Dermatol Ges. Jul 2005;3(7):530-1. [Medline].
  • Holme SA, McHenry P. Nodular presentation of eosinophilic cellulitis (Wells'' syndrome). Clin Exp Dermatol. Nov 2001;26(8):677-9. [Medline].
  • Hurni MA, Gerbig AW, Braathen LR, Hunziker T. Toxocariasis and Wells'' syndrome: a causal relationship?. Dermatology. 1997;195(4):325-8. [Medline].
  • Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. Sep 12 1994;154(17):1983-4. [Medline].
  • Leiferman KM, Peters MS. Reflections on eosinophils and flame figures: where there's smoke there's not necessarily Wells syndrome. Arch Dermatol. Sep 2006;142(9):1215-8. [Medline].
  • Moossavi M, Mehregan DR. Wells'' syndrome: a clinical and histopathologic review of seven cases. Int J Dermatol. Jan 2003;42(1):62-7. [Medline].
  • Mutasim DF, Cooper CH. A case of Wells' syndrome in a patient with lymphocytic lymphoma. Geriatr Dermatol. 1996;4(1):11-14.
  • Newton JA, Greaves MW. Eosinophilic cellulitis (Well''s syndrome) with florid histological changes. Clin Exp Dermatol. Sep 1988;13(5):318-20. [Medline].
  • Nielsen T, Schmidt H, Sogaard H. Eosinophilic cellulitis. (Well''s syndrome) in a child. Arch Dermatol. Jul 1981;117(7):427-9. [Medline].
  • Odia SG, Purschel W, Worret WI, Rakoski J. Hypereosinophilic cellulitis(Wells' syndrome) resembling urticaria. Acta Derm Venerol (Ljubljana). 1994;6:193-195.
  • Peters MS, Schroeter AL, Gleich GJ. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells'' syndrome. Br J Dermatol. Aug 1983;109(2):141-8. [Medline].
  • Plotz SG, Abeck D, Behrendt H, et al. [Eosinophilic cellulitis (Wells syndrome)]. Hautarzt. Mar 2000;51(3):182-6. [Medline].
  • Spigel GT, Winkelmann RK. Wells'' syndrome. Recurrent granulomatous dermatitis with eosinophilia. Arch Dermatol. May 1979;115(5):611-3. [Medline].
  • Stern JB, Sobel HJ, Rotchford JP. Wells'' syndrome: is there collagen damage in the flame figures?. J Cutan Pathol. Dec 1984;11(6):501-5. [Medline].
  • Tsuda S, Tanaka K, Miyasato M, et al. Eosinophilic cellulitis (Wells'' syndrome) associated with ascariasis. Acta Derm Venereol. Jul 1994;74(4):292-4. [Medline].
  • Wells GC, Smith NP. Eosinophilic cellulitis. Br J Dermatol. Jan 1979;100(1):101-9. [Medline].
  • Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc. 1971;57(1):46-56. [Medline].
  • van den Hoogenband HM. Eosinophilic cellulitis as a result of onchocerciasis. Clin Exp Dermatol. Jul 1983;8(4):405-8. [Medline].

Wells Syndrome (Eosinophilic Cellulitis) excerpt

Article Last Updated: Feb 1, 2007